Community-acquired Infections
📧 Sign up to get email alerts when something new happens for Community-acquired Infections.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-01-13Clinical Trial Update: Sepsis-3 Study in Northeast Thailand
A completed Sepsis-3 clinical trial conducted in Northeast Thailand, sponsored by the University of Oxford, focusing on sepsis and community…
-
EMA approval · 2025-03-05EMA Authorised: Quofenix (delafloxacin meglumine) — A. Menarini Industrie Farmaceutiche Riunite s.r.l.
EMA has authorised Quofenix, a delafloxacin meglumine antibacterial product, for the treatment of community-acquired infections. Decision da…
-
CLINICAL_TRIALS research · 2024-11-26Clinical Trial Update: Clinical and Ecological Impact of a Primary Care Antimicrobial Stewardship Program Based on Telematic Educational Interviews (TELÉMACO Trial) [NA]
A clinical trial update on the TELÉMACO trial evaluating the clinical and ecological impact of a telematic educational interview–based antim…
-
EMA withdrawal · 2019-06-19EMA Withdrawn: Ketek (telithromycin) — Aventis Pharma S.A.
Telithromycin (Ketek) has been withdrawn from the European market by Aventis Pharma S.A. after regulatory assessment.
-
CLINICAL_TRIALS research · 2012-09-14Clinical Trial Update: Validation of Vital Signs and Symptoms for the Diagnosis of Serious Infections in Children in the Paediatric A&E.
A clinical trial update describing validation of vital signs and symptoms for diagnosing serious infections in children presenting to the pa…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.